Keyphrases
Active Disease
9%
Adalimumab
100%
American College of Rheumatology
9%
Between-group
9%
C-reactive Protein
9%
Clinical Activity Score
9%
Clinical Outcomes
100%
Clinical Response
18%
Disability
9%
Disease Activity
9%
Disease Activity Score
9%
Disease Activity Score 28 (DAS28)
9%
Disease Control
9%
Disease-modifying Antirheumatic Drugs (DMARDs)
54%
Drug Groups
9%
Drug Therapy
9%
Drug-naïve Patients
9%
Early Rheumatoid Arthritis
27%
European League against Rheumatism (EULAR)
9%
First Year
9%
Hydroxychloroquine
9%
Induction Therapy
27%
Intra-articular
100%
Investigator-initiated
100%
Methotrexate
100%
Opera
100%
Placebo
9%
Profile Response
9%
Quality of Life Changes
9%
Radiographic Changes
9%
Radiographic Outcomes
100%
Radiographic Progression
9%
Randomized Controlled Trial
100%
Remission
9%
Remission Rate
9%
Simplified Disease Activity Index
9%
Sulfasalazine
9%
Swollen Joint
9%
Synthetic Disease-modifying Antirheumatic Drugs
9%
Synthetic DMARDs
9%
Targeted Treatment
9%
Total Sharp Score
9%
Treat-to-target
100%
Treatment Profiles
9%
Treatment Withdrawal
9%
Trial Registration
9%
Triamcinolone
27%
Triamcinolone Acetonide
9%
Medicine and Dentistry
Adalimumab
100%
C Reactive Protein
9%
Clinical Disease Activity Index
9%
Clinical Study
9%
DAS28
9%
Disease
18%
Disease Activity
9%
Disease Activity Score
9%
Disease Modifying Antirheumatic Drug
63%
Disease-Modifying Antirheumatic Drug
9%
Drug Induced Disease
9%
Drug Therapy
9%
Glucocorticoid
100%
Hydroxychloroquine
9%
Methotrexate
100%
Placebo
9%
Quality of Life
9%
Randomized Controlled Trial
100%
Rheumatic Disease
9%
Rheumatoid Arthritis
27%
Rheumatology
9%
Salazosulfapyridine
9%
Simplified Disease Activity Index
9%
Spontaneous Remission
9%
Treatment Withdrawal
9%
Triamcinolone
27%
Triamcinolone Hexacetonide
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
100%
C Reactive Protein
9%
Clinical Study
9%
Disease
18%
Disease Activity
27%
Disease Activity Score
9%
Disease Modifying Antirheumatic Drug
63%
Drug Induced Disease
9%
Glucocorticoid
100%
Hydroxychloroquine
9%
Methotrexate
100%
Pharmacotherapy
9%
Placebo
9%
Randomized Controlled Trial
100%
Remission
18%
Rheumatic Disease
9%
Rheumatoid Arthritis
27%
Sulfasalazine
9%
Triamcinolone
27%
Triamcinolone Hexacetonide
9%
Immunology and Microbiology
Adalimumab
100%
C-Reactive Protein
9%
Disease-Modifying Antirheumatic Drug
63%
Glucocorticoid
100%
Hydroxychloroquine
9%
Inflammatory Arthritis
27%
Methotrexate
100%
Rheumatic Disease
9%
Sulfasalazine
9%
Triamcinolone
36%